Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer — TIMEPAN

Metastatic Pancreas Cancer Clinical Trial

Official title:
TIming of Start of systemIc Treatment for Asymptomatic MEtastasized PANcreatic Cancer (TIMEPAN): a Randomized Controlled Multicenter Trial

Status Recruiting

Clinical Trial Summary

Since patients with metastatic pancreatic cancer have a limited life expectancy, it is important to determine the timing of when to start chemotherapy in order to optimize the benefits of chemotherapy relative to the side effects. Therefore, two treatment strategies can be considered: chemotherapy started immediately at diagnosis, or delayed until disease-related symptoms occur.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04897854
Study type	Interventional
Source	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact	J.W. Wilmink, Dr.
Phone	+31 20 5628065
Email	j.w.wilmink@amsterdamumc.nl
Status	Recruiting
Phase	Phase 3
Start date	April 22, 2021
Completion date	April 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03126435` - EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX	Phase 3
Recruiting	`NCT01586611` - A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer	Phase 3
Withdrawn	`NCT02885727` - Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)	Phase 2